"Metformin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
| Descriptor ID |
D008687
|
| MeSH Number(s) |
D02.078.370.141.450
|
| Concept/Terms |
Metformin- Metformin
- Dimethylbiguanidine
- Dimethylguanylguanidine
|
Below are MeSH descriptors whose meaning is more general than "Metformin".
Below are MeSH descriptors whose meaning is more specific than "Metformin".
This graph shows the total number of publications written about "Metformin" by people in this website by year, and whether "Metformin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 1 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 0 | 2 |
| 2006 | 1 | 1 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 3 | 1 | 4 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 2 | 4 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 3 | 4 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 2 | 3 |
| 2018 | 3 | 2 | 5 |
| 2019 | 4 | 1 | 5 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Metformin" by people in Profiles.
-
Parajuli S, Jasmin G, Sirak H, Lee AF, Nwosu BU. Prediabetes: Adherence to Nutrition Visits Decreases HbA1c in Children and Adolescents. Front Endocrinol (Lausanne). 2022; 13:916785.
-
Malin SK, Braun B. Are we closer to providing better guidance for prescribing metformin and exercise to patients? Obesity (Silver Spring). 2022 06; 30(6):1141-1142.
-
Raza A, Murtaza SH, Hanif S, Iqbal J, Ali I, Aftab T, Shakir R, Bedar R, Syed MA. Validation of a rapid and economical RP-HPLC method for simultaneous determination of metformin hydrochloride and sitagliptin phosphate monohydrate: Greenness evaluation using AGREE score. Pak J Pharm Sci. 2022 Jan; 35(1):15-21.
-
Moore E, Reynolds JA, Davidson A, Gallucci S, Morel L, Rao DA, Young HA, Putterman C. Promise and complexity of lupus mouse models. Nat Immunol. 2021 06; 22(6):683-686.
-
Böhme J, Martinez N, Li S, Lee A, Marzuki M, Tizazu AM, Ackart D, Frenkel JH, Todd A, Lachmandas E, Lum J, Shihui F, Ng TP, Lee B, Larbi A, Netea MG, Basaraba R, van Crevel R, Newell E, Kornfeld H, Singhal A. Metformin enhances anti-mycobacterial responses by educating CD8+ T-cell immunometabolic circuits. Nat Commun. 2020 10 16; 11(1):5225.
-
Kumar NP, Moideen K, Nancy A, Viswanathan V, Shruthi BS, Sivakumar S, Hissar S, Kornfeld H, Babu S. Systemic RAGE ligands are upregulated in tuberculosis individuals with diabetes co-morbidity and modulated by anti-tuberculosis treatment and metformin therapy. BMC Infect Dis. 2019 Dec 09; 19(1):1039.
-
Linden MA, Ross TT, Beebe DA, Gorgoglione MF, Hamilton KL, Miller BF, Braun B, Esler WP. The combination of exercise training and sodium-glucose cotransporter-2 inhibition improves glucose tolerance and exercise capacity in a rodent model of type 2 diabetes. Metabolism. 2019 08; 97:68-80.
-
Lal A, Kaur N, Trivedi N. Metformin, arterial contrast and acute kidney Injury. Acta Biomed. 2019 05 23; 90(2):355-356.
-
Magee MJ, Salindri AD, Kornfeld H, Singhal A. Reduced prevalence of latent tuberculosis infection in diabetes patients using metformin and statins. Eur Respir J. 2019 03; 53(3).
-
Alcusky M, Keith SW, Karagiannis T, Rabinowitz C, Louis DZ, Maio V. Metformin exposure and survival in head and neck cancer: A large population-based cohort study. J Clin Pharm Ther. 2019 Aug; 44(4):588-594.